Lundbeck sells preclinical drugs to former research exec

The focus on four psychiatric disorders has made Lundbeck sell off two preclinical research projects to a US-based company founded by the former Vice President of the company's US research department. Lundbeck may still profit from the drugs, as there is an option for milestones and royalties.

Two drugs originally developed as possible treatments for psychiatric disorders no longer fit with Lundbeck's business plan, and have therefore been sold. Photo: Lundbeck

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Nævn afviser tilskud til Novos fedmemiddel

Prisen for fedmemidlet Saxenda fra Novo Nordisk står ikke mål med effekten, mener Lægemiddelstyrelsens Medicintilskudsnævn, der har indstillet til, at danske patienter ikke skal have tilskud til behandling med midlet uden en særlig god forklaring.

Related articles